Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma

In the last two decades, various therapies have been introduced for lung carcinoma patients, including tyrosine-kinase inhibitors for different mutations. While some of them are specific to specific tumor types, others, like NTRK1–3 fusions, are found in various solid tumors. The occurrence of an NT...

Descripción completa

Detalles Bibliográficos
Autores principales: Strohmeier, Simon, Brcic, Iva, Popper, Helmut, Liegl-Atzwanger, Bernadette, Lindenmann, Jörg, Brcic, Luka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105314/
https://www.ncbi.nlm.nih.gov/pubmed/33963267
http://dx.doi.org/10.1038/s41598-021-89373-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105314/
https://www.ncbi.nlm.nih.gov/pubmed/33963267
http://dx.doi.org/10.1038/s41598-021-89373-3

Ejemplares similares